Who are Miralax's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pizensy, Cephulac, Milk of Magnesia, Polyethylene glycol / Ascorbic acid, PEG 3350, Miralax (PEG 3350).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/macrogol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Miralax — Competitive Intelligence Brief

Miralax (Macrogol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Osmotic Laxative [EPC]. Area: Ophthalmology.

marketed Osmotic Laxative [EPC] Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Miralax (Macrogol) — Braintree.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Miralax TARGET	Macrogol	Braintree	marketed	Osmotic Laxative [EPC]		1984-01-01
Pizensy	LACTITOL	Braintree Labs	marketed	Osmotic Laxative		2020-01-01
Cephulac	LACTULOSE	Sanwa Kagaku Kenkyusho Co., Ltd.	marketed	Osmotic Laxative [EPC]		1976-01-01
Milk of Magnesia	magnesium hydroxide	Generic (multiple manufacturers)	marketed	Osmotic laxative, Antacid	Gastric acid (direct neutralization) + osmotic effect in intestine	1880-01-01
Polyethylene glycol / Ascorbic acid	Polyethylene glycol / Ascorbic acid	Tomas Bata Hospital, Czech Republic	marketed	Osmotic laxative with antioxidant supplement
PEG 3350	PEG 3350	Hamilton Health Sciences Corporation	marketed	Osmotic laxative
Miralax (PEG 3350)	Miralax (PEG 3350)	Brooke Army Medical Center	marketed	Osmotic laxative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-03-09 — Miralax · 10780112 · US
2032-03-09 — Miralax · 11529368 · US
2032-03-09 — Miralax · 10792306 · US
2032-03-25 — Miralax · 10646512 · US
2032-08-11 — Miralax · 9592252 · US
2033-09-10 — Miralax · 9326969 · US
2033-09-10 — Miralax · 9707297 · US
2033-09-10 — Miralax · 8999313 · US
2033-09-10 — Miralax · 10918723 · US
2033-09-10 — Miralax · 10016504 · US

Sponsor landscape (Osmotic Laxative [EPC] class)

Braintree · 1 drug in this class
Sanwa Kagaku Kenkyusho Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Miralax — Competitive Intelligence Brief. https://druglandscape.com/ci/macrogol. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab